ArticleTherapeutic advances in endocrinology and metabolism2026
Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report.
Article in Therapeutic advances in endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Automated insulin delivery (AID) is the gold standard of treatment for type 1 diabetes mellitus (T1DM). However, little data on the use in people on peritoneal dialysis (PD) exist. To share real-world experience on the use of AID (Medtronic MiniMed 780G SmartGuard and Guardian 4 continuous glucose monitoring system) in a woman living with type 1 diabetes on PD, we report the implementation despite the complex setting of type 1 diabetes with multiple diabetes-associated complications, PD, visual impairment, and a complete language barrier. Glycemic control 14 days before the start of AID on multiple daily injections and 9 months after the conversion is presented. AID might be a safe and promising therapeutic option for individuals with T1DM and end-stage kidney disease requiring PD. Further research is needed to demonstrate both safety and efficacy in this special population, and assessment of patient-reported outcome measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.